Sign in
Not yet recruitingNo phase

Fast gene testing for children with familial lymphohistiocytosis

Tests very fast gene sequencing to diagnose familial lymphohistiocytosis in children.

Key facts

Who runs it
Assistance Publique Hopitaux De Marseille
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Impact of Ultra-fast Genetic Diagnosis of Familial Lymphohistiocytosis on the Time to Bone Marrow Transplantation and Overall Survival
Status
Not yet recruiting
People taking part
240 people, planned
Started
Oct 2026
Expected to end
Oct 2030
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Third-generation sequencing
Record updated
3 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children with confirmed or suspected familial lymphohistiocytosis (FHL), or a related genetic syndrome. It tests a very fast genetic test to speed up diagnosis and the path to bone marrow transplant.

Age
Under 18 years
Sex
All
Disease stage
Confirmed or suspected FHL or a related genetic syndrome that leads to HLH (for example Griscelli Syndrome, Chédiak-Higashi Syndrome, XLP1, XLP2). A family history of lymphohistiocytic activation syndrome also counts. Children must have at least 5 of 8 HLH signs. These include fever, a large spleen, low blood counts and high ferritin.
Biomarker or test result
At least 5 of these: fever; enlarged spleen; triglycerides ≥ 3 mmol/l (266 mg/dL) and/or fibrinogen ≤ 1.5g/l; hemophagocytosis in a tissue sample; low or absent NK function (<10% of the laboratory normal); ferritin ≥ 500μg/l; soluble CD25 ≥ 2,400U/ml or activated T cells; low counts in at least two blood cell lines (haemoglobin < 9.0 g/dl, platelets <100 G/L, neutrophils <1,0 G/L).

Main reasons for not taking part

  • Age 18 years or older
  • Solid tumor, leukemia or lymphoma
  • Pregnant or breastfeeding, under guardianship, or deprived of liberty
  • Not understanding French
  • In the exclusion period of another study

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Children under 18 years old
  • Confirmed or suspected diagnosis of FHL or a related genetic syndrome predisposing to HLH (e.g. Griscelli Syndrome, Chédiak-Higashi Syndrome, XLP1, XLP2) or a family history of lymphohistiocytic activation syndrome
  • Presence of at least 5 of the 8 following criteria (diagnostic criteria according to the definition of the "Histiocyte Society" (1)):; Fever; Splenomegaly; Hypertriglyceridemia ≥ 3 mmol/l and/or hypofibrinogenemia≤ 1.5g/l; Hemophagocytosis found in a histological sample; Decreased or absent NK function (<10% of the laboratory normal); Ferritin ≥ 500μg/l; Soluble CD25 ≥ 2,400U/ml or presence of activated T cells in phenotyping; Cytopenia (affecting at least two blood cell lines): Haemoglobin < 9.0 g/dl, Platelets <100 G/L, Neutrophils <1,0 G/L
  • Patient benefiting from social security coverage
  • The legal guardian(s) who have signed the informed consent form

Who cannot take part

  • Age ≥ 18 years
  • Solid tumor, leukemia, lymphoma
  • Subjects covered by articles L1121-5 to 1121-8 of the public health code (patients under guardianship or curatorship, patient deprived of liberty, pregnant or breadtfeeding woman)
  • Persons who do not understand the French language
  • Patient in the exclusion period of another research protocol at the time of signing the consent form

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Familial lymphohistiocytosis (FHL) is a group of rare genetic diseases (around fifteen cases per year in France). The defect in T lymphocyte cytotoxicity resulting from this disease is responsible for hemophagocytic lymphohistiocytosis (HLH). Promptly treatment of HLH is essential for prognosis. These diseases are fatal without a bone marrow transplant, with an overall 5-year survival rate of no more than 80% for FHL. The genetic or acquired nature of HLH is not easy to determine. An infectious trigger can be confounding when it occurs in an FHL. But above all, functional biological tests demonstrating a T lymphocyte cytotoxicity defects are difficult to interpret. Genetic diagnosis is therefore essential for confirming the primary nature of HLH, and for initiating targeted treatments (first stage: putting HLH into remission with chemotherapy or immunotherapy; second stage: bone marrow transplant). Genetic diagnosis of FHL is therefore a matter of emergency, and is currently based on targeted gene panel exploration (fragmentation sequencing) requiring 6 to 8 weeks. Recently, the development of third-generation sequencing (TGS) has revolutionized genomic medicine, enabling unitary sequencing in real time. As a result of this innovation, certain private molecular diagnostic specialties can now access this new emergency genomic medicine.

Read full original descriptionShow less

Aim: the main aim of this study is to demonstrate the feasibility of a national circuit for ultra-rapid genetic diagnosis of pediatric HLH revealing familial lymphohistiocytosis. The secondary objective is to evaluate the impact of this early genetic diagnosis on the delay to remission of HLH and the delay to transplantation.

Methods: This prospective, multicenter study measures the time required for genetic diagnosis of FHL in pediatric HLH, using innovative TGS sequencing technology.

Perspectives: Fast genomic diagnosis of FHL will considerably shorten the time to confirm the diagnosis, to obtain HLH remission and, finally, to reach transplantation faster.

The 2 groups in the trial

  • Prospectif GroupTreatment being tested

    Group of 200 patients who will be tested prospectively

    Treatment: Third-generation sequencing

  • Retrospectif GroupNo study treatment, for comparison

    Group of 40 patients whose data will be retrospectivly compared to the prospectif group

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Ultra-rapid Genetic Diagnosis of Primary Haemophagocytic Lymphohistiocytosis on the Time to Haematopoietic Stem Cell Transplantation
Plain-language title
Fast gene testing for children with familial lymphohistiocytosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
3 August 2026